Scientific Secondary Proof

Authoritative publication in international journals

In November 2021, the famous anti-aging scientist Professor Brian Kennedy published an article in the top journal "Trends in Endocrinology & Metabolism" in the field of metabolism and endocrinology, detailing the regulatory role of GeneAKG® in aging and the treatment of aging.

Conclusions from human experiment research

A human study in the United States concluded that by supplementing the dietary supplement AKG, the degree of DNA methylation of users was significantly changed, the average biological age was reversed by 8.5 years, and the oldest user was even reversed by 34 years.

Authoritative publication in international journals

In 2014, a study published in the top journal "Nature" showed that it extended the lifespan of nematodes by 50% by inhibiting ATP synthase activity and the mTOR pathway. In addition, it can activate AMPK, promote autophagy, and significantly prolong the lifespan of Drosophila. AKG has been found to be beneficial in extending the healthy lifespan of yeast, nematodes, fruit flies and mice.

Authoritative publication in international journals

In November 2020, the article "Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations" published in "Nature Communications“.The article expounds the role of GeneAKG® in restoring bone marrow mesenchymal stem cells and improving age-related osteoporosis, which has good therapeutic potential in age-related diseases.

Experimental Data

Supplementation with GeneAKG® also significantly upregulated the transcript levels of autophagy-related genes Atg1, Atg5, Atg8a and Atg8b, increasing autophagy. (A) Relative mRNA expression of genes downstream and upstream of mTOR. (B) Relative mRNA expression of autophagy-related genes. (C) Phagosome staining.

GeneAKG® Phase I human clinical trial report

The results of this trial showed that after taking GENEAKG, the 29 patients with various types of chronic diseases who participated in the trial had better condition of insomnia, memory loss, fatigue, proteinuria, renal failure, chronic allergic cough, stroke sequelae, and enlarged prostate. Symptoms such as urinary retention, Covid-19 sequelae and other symptoms have been significantly cured or improved.

The most impressive outcome was that after taking Ca-AKG, the mice’s healthspan was prolonged, and frailty was significantly reduced.

At the end of 2020, researchers at the University of Southern California and the National University of Singapore published in Cell Metabolism a paper entitled “Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice.” Their study found that that supplementing with the natural metabolite AKG (hence GeneAKG®) significantly prolonged the lifespan and survival of mice, reduced their morbidity and inflammatory cytokines, greatly improved aging phenotypes such as coat color loss and hunchback development, and made the mice healthier. This is also the first in-depth study of the effects of CaAKG in mammals. Notably, Ca-AKG supplementation significantly increased the survival rate of female mice in the two experiments conducted. Compared with the control, Ca-AKG supplementation significantly prolonged the median life span and survival rate of female mice by 16.6% and 19.7%, respectively, in the first experiment, and by 10.5% and 8%, respectively, in the second experiment. Ca-AKG supplementation prolonged the median lifespan of male mice by 9.6% and 12.8%. Ca-AKG treatment significantly reduced the severity of various agedependent phenotypes such as loss of coat color, striated hair, dermatitis, an unstable gait, and a hunchback in female mice. In male mice, the physical condition, dermatitis, gait disturbance, eye discharge, kyphosis, and tumors were also improved. Importantly, no significant adverse effects of AKG treatment were found.